The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

@article{Nelson2007TheIM,
  title={The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.},
  author={Patric Nelson and Terri Poon and Xuesong Guan and Catherine A. Schnabel and Matthew E Wintle and Mark S Fineman},
  journal={Diabetes technology & therapeutics},
  year={2007},
  volume={9 4},
  pages={
          317-26
        }
}
BACKGROUND Exenatide is an adjunctive therapy for type 2 diabetes, and preliminary evidence suggests that its glucoregulatory effects may be similar in the absence of oral therapy. METHODS Study A was a randomized, double-blind, placebo-controlled study of 99 patients with type 2 diabetes that received either 10 microg twice-daily, 10 microg once-daily, or 20 microg once-daily exenatide or placebo for 28 days in the absence of background pharmacotherapy. Study B was an open-label extension of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS

Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus

  • Diabetology & Metabolic Syndrome
  • 2012
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED